Jianhui Wu

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).

Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).

Journal: British journal of cancer

Published: January 21, 2026

AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes.

AGR2-high cells drive a FOXM1-mediated pro-malignancy program in non-functional pancreatic neuroendocrine tumors (NF-PanNETs) and informatively predict patient outcomes.

Journal: Science bulletin

Published: December 11, 2025

18F-FDG PET/CT manifestations of extra-adrenal retroperitoneal ganglioneuroma: a retrospective study of 21 cases.

18F-FDG PET/CT manifestations of extra-adrenal retroperitoneal ganglioneuroma: a retrospective study of 21 cases.

Journal: Annals of nuclear medicine

Published: October 10, 2025

Proteomics Profiling Identifies MCM4 as a Prognostic Biomarker for Postoperative Metastasis in Solid Pseudopapillary Neoplasms of the Pancreas.

Proteomics Profiling Identifies MCM4 as a Prognostic Biomarker for Postoperative Metastasis in Solid Pseudopapillary Neoplasms of the Pancreas.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: September 30, 2025

Radioresistance in Hepatocellular Carcinoma: Biological Bases and Therapeutic Implications.

Radioresistance in Hepatocellular Carcinoma: Biological Bases and Therapeutic Implications.

Journal: International journal of molecular sciences

Published: December 29, 2024

Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression.

Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression.

Journal: International journal of biological sciences

Published: December 11, 2024

Minimally Invasive Unilateral Pedicle Combined With Contralateral Translaminar Facet Joint Screw Fixation for Single-Segment Lumbar Degenerative Disease: A 10-Year Follow-Up Study.

Minimally Invasive Unilateral Pedicle Combined With Contralateral Translaminar Facet Joint Screw Fixation for Single-Segment Lumbar Degenerative Disease: A 10-Year Follow-Up Study.

Journal: Spine

Published: September 18, 2024

Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis.

Phase II trial of hepatic arterial infusion chemotherapy plus bevacizumab and toripalimab for advanced biliary tract cancers: efficacy, safety, and exploratory analysis.

Journal: Hepatobiliary surgery and nutrition

Published: August 22, 2024

Core-fucosylated glycoproteins as biomarkers for diagnosing pancreatic ductal adenocarcinoma.

Core-fucosylated glycoproteins as biomarkers for diagnosing pancreatic ductal adenocarcinoma.

Journal: International journal of biological macromolecules

Published: August 18, 2024

Surgical outcomes of major vascular resection for retroperitoneal liposarcoma from a high‑volume sarcoma center: a propensity score matching analysis.

Surgical outcomes of major vascular resection for retroperitoneal liposarcoma from a high‑volume sarcoma center: a propensity score matching analysis.

Journal: Journal of cancer research and clinical oncology

Published: April 28, 2024

Bibliometric analysis of liposarcomas treatment from 2004 to 2023.

Bibliometric analysis of liposarcomas treatment from 2004 to 2023.

Journal: Journal of cancer research and clinical oncology

Published: April 15, 2024

Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma.

Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma.

Journal: Therapeutic advances in medical oncology

Published: February 11, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026